Tyche Wealth Partners LLC Cuts Position in Johnson & Johnson (NYSE:JNJ)

Tyche Wealth Partners LLC reduced its holdings in Johnson & Johnson (NYSE:JNJ) by 4.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 26,654 shares of the company’s stock after selling 1,188 shares during the period. Johnson & Johnson comprises 1.0% of Tyche Wealth Partners LLC’s holdings, making the stock its 24th largest position. Tyche Wealth Partners LLC’s holdings in Johnson & Johnson were worth $4,320,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Mirador Capital Partners LP boosted its holdings in Johnson & Johnson by 4.2% in the 1st quarter. Mirador Capital Partners LP now owns 20,508 shares of the company’s stock worth $3,244,000 after buying an additional 833 shares during the last quarter. Aviance Capital Partners LLC boosted its stake in shares of Johnson & Johnson by 63.3% in the first quarter. Aviance Capital Partners LLC now owns 37,818 shares of the company’s stock worth $5,982,000 after acquiring an additional 14,663 shares during the last quarter. Skyline Advisors Inc. increased its position in shares of Johnson & Johnson by 3.5% during the first quarter. Skyline Advisors Inc. now owns 2,478 shares of the company’s stock worth $392,000 after purchasing an additional 83 shares in the last quarter. Wolff Wiese Magana LLC raised its stake in Johnson & Johnson by 8.0% in the 1st quarter. Wolff Wiese Magana LLC now owns 3,950 shares of the company’s stock valued at $625,000 after purchasing an additional 294 shares during the last quarter. Finally, BKM Wealth Management LLC lifted its holdings in Johnson & Johnson by 16.3% in the 1st quarter. BKM Wealth Management LLC now owns 14,473 shares of the company’s stock valued at $2,289,000 after purchasing an additional 2,025 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on JNJ. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Morgan Stanley raised their target price on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price target for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. Citigroup boosted their price objective on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Finally, TD Cowen cut their target price on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Six research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $175.93.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Up 0.3 %

NYSE JNJ opened at $160.62 on Thursday. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The stock has a market capitalization of $386.56 billion, a P/E ratio of 10.01, a PEG ratio of 2.90 and a beta of 0.52. The firm’s 50-day moving average is $163.44 and its two-hundred day moving average is $155.32. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.46%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the company posted $2.66 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.09%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.